AVANIR Pharmaceuticals (AVNR) has completed targeted enrollment of patients into the STAR trial, a confirmatory Phase III trial of Zenvia(TM) (dextromethorphan/quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA). The randomized, multi-center, international STAR trial is designed to compare the effects of Zenvia 30/10 mg, Zenvia 20/10 mg and placebo on involuntary crying/laughing episodes rates.
The STAR trial had a targeted enrollment of 120 patients with multiple sclerosis (MS) and 180 patients with amyotrophic lateral sclerosis (ALS) who exhibit signs and symptoms of PBA at approximately 50 sites in the U.S. and Latin America. The primary efficacy analysis is based on the changes in crying/laughing episode rates recorded in patient diaries.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index